MAP2K1 and neoplasm: In a phase I trial (NCT01061749), the association of cixutumumab with the MEK1/2 inhibitor selumetinib, improved time to tumor progression [62], while a nonrandomized open label phase I trial (NCT01204476) tested the association of cixutumumab with the mTOR inhibitor everolimus and octreotide in several tumor types including medullary thyroid carcinoma.